Recombinant anti-Human CD28 mAb(Cat. No.:GMP-A063) novoprotein
$50.00
In stock
SKU
GMP-A063
50μg: Inquiry
500μg: Inquiry
1mg: Inquiry
Description
CD28 molecule is present on the surface of most T cells and is considered a surface molecule unique to T cells. However, not only the first signal of the T lymphocyte receptor (TCR)/CD3 complex is required during the full activation of T lymphocytes, but also the second signal, to enhance the activation and proliferation of T lymphocytes. The synergistic stimulation molecule CD28 is present on the surface of T lymphocytes, and its interaction with its ligand B7 is one of the major pathways to provide the second signal for T lymphocyte activation. T lymphocytes will be fully activated if the second signal is provided through the synergistic stimulation of the CD28 antibody while providing the first signal using the simulation of the CD3 antibody in vitro.
Recombinant Anti-Human CD28 mAb is expressed by mammalian cells, and is produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.
Usage
In-vitro cultivation of various types of cell.
Recombinant Anti-Human CD3 mAb can satisfy most T cell expansion requirements and exhibit the same effects as OKT3. For difficult-to-expand cells, the product can be used in combination with Recombinant Anti-Human CD28 mAb (Cat. No: GMP-A063) or NovoNectin® GMP Grade (Cat. No.: GMP-CH38).
Product Details
| Item | Details |
| Storage | Storage at -20±5℃, expiration date labeled on bottle. |
Quality Control
| Item | Standard |
| Appearance | Transparent liquid |
| Visible particle | Conform to ChP |
| pH value | 6.9–7.9 |
| Purity | ≥ 95% |
| Bioactivity | ≤ 100 ng/mL |
| Endotoxin | < 10 EU/mg |
| Host protein | ≤ 0.005% |
| Exogenous DNA residue | ≤ 100 pg/mg |
| Mycoplasma test | Negative |
| Sterility test | Conform to ChP |
Product Details
| Item | Details |
| Recommendations | （1）Make sure the product properly stored and none expired before using. （2）Sterile condition without pyrogen is required for reconstitution, re-aliquoting, dilution. （3）After reconstitution, aliquoted solution vials should be stored at -70°C and minimize freeze-thaw cycles preventing denaturation of protein. Applications in T cell activation and expansion: General applications: The recommended concentration is 5–10 μg/mL; if necessary, the optimal concentration for specific cells can be selected at 5–20 μg/mL. Coating of culture flask: a.Calculate the volume on the basis of 150 μL/cm2, dilute the Recombinant Anti-Human CD3 mAb, recombinant anti-CD28 mAb, and NovoNectin® GMP Grade with normal saline to 5–10 μg/mL, 5–10 μg/mL, and 25–50 μg/mL, respectively, and mix them to a coating solution; b.Add the diluted coating solution to a culture flask or bag and cover the bottom with the solution; c.Place the solution in a 37 °C incubator for 5–8 h, or at 2–5 °C overnight; d.Remove the liquid and wash the flask or bag 3 times with normal saline; e.The well-coated culture vessel shall be used immediately; if the vessel is to be used after more than 30 minutes, store it in normal saline. |
title: CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL
authors: Yan Yang, Wei Lu, Zhexi Zhu, Chenyang Li, Zihao Guo, Han Zhang
date: 2026/06/11
journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
title: Deoxyelephantopin, a natural sesquiterpene lactone, suppresses IL-2 production of ConA-activated T lymphocytes through inhibiting NF-κB and calcineurin/NFAT signaling
authors: Min Cai, Ruijuan Qi, Muqing Wang, Congyu Wu, Qian Chen, Yilin Guo, Yu Liu, Xin Huang, Yuan Gao, Yun Qi
date: 2026/05/30
journal: EUROPEAN JOURNAL OF PHARMACOLOGY
title: Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy
authors: Haigang Geng, Hongye Wang, Chuanjie Zhang, Yangyang Zhou, Yiqing Zhong, Zhenhua Zhu, Zhaorong Wu, Tangansu Zhang, Nuo Xu, Zhongyi Dong, Haoyu Zhang, Qian Li, Yan Li, Xiangyu Tang, Xifu Cheng, Xiang Xia, Zizhen Zhang, Bo Zhai, Zhigang Zheng, Qing Li, Chen Yang, Chunchao Zhu
date: 2026/03/26
journal: DEVELOPMENTAL CELL
title: KRASG12V/HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors
authors: Huimin Shao, Fei Xu, Jiangyue Xu, Lingjie Zhou, Yao Wu, Lianjun He, Xueyi Qian, Weijie He, Nanlin Jiao, Yabin Xia, Jun Zhao, Lili Sheng, Guoliang Mao, Tao Ma, Wei Wang, Shaoxiang Luo, Li Fu, Zhenyu Xu
date: 2026/2/20
journal: Science Advances
title: Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
authors: Du Sicheng, Zhang Ying, Hao Ruidong, Qiu Lupeng, Li Chao, Li Yuting, Liu Rong-Rui, Zhao Chuan-Hua, Li Juan, Ye Sisi, Zhou Jun, Li Yantao, Yi Qiaoyong, Zhang Shuangshuang, Sun Minmin, Luo Tianhang, Xu Jianming
date: 2025/11/28
journal: MOLECULAR CANCER THERAPEUTICS
title: Dysfunctional glycolysis-UCP2-fatty acid oxidation promotes CTLA4intFOXP3int regulatory T-cell production in rheumatoid arthritis
authors: Han Jiawen, Zhou Zhongyang, Wang Hongxia, Chen Yuxin, Li Wuguo, Dai Meiqin, Bian Jing, Zhao Erming, He Jiaying, Zhang Xinyao, Yi Huanfa, Shao Lan
date: 2025/10/09
journal: MOLECULAR MEDICINE
title: Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor
authors: Sun Minmin, Bian Linke, Wang Hongye, Liu Xin, Li Yantao, Wu Zhaorong, Zhang Shuangshuang, Hao Ruidong, Xin Hong, Zhai Bo, Zhang Xuemei, Cheng Yuanguo
date: 2025/06/19
journal: CELLULAR ONCOLOGY
title: IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment
authors: Wu Zhaorong, Wang Hongye, Zheng Zhigang, Lin Yan, Bian Linke, Geng Haigang, Huang Xiaorong, Zhu Jiufei, Jing Hongshu, Zhang Yi, ji Chen, Zhai Bo
date: 2025/03/05
journal: Journal of Translational Medicine
title: A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells
authors: Fuhua Wu, Zhaofei Guo, Jialiang Yang, Yangsen Ou, Xiejin Xie, Hu Liao, Chenqi Guo, Yuxi Zhan, Haiping Wu, Rui Hu, Yanhua Xu, Xue Tang, Haolin Wang, Lin Ye, Penghui He, Chunting He, Lu Huang, Shuang Luo, Xun Sun, Zhenglin Yang
date: 2025/01/21
journal: ADVANCED MATERIALS
title: YAP1 mediates the dimensional and chemical coordination of immunoregulation and therapy in extensively passaged mesenchymal stem cells
authors: Fang-Ying Du, Feng Zhou, Na Zhao, Lei Bao, Cheng-Biao Hu, Jing Lei, An-Qi Liu, Ying-Feng Gao, Li-Hui Bao, Hua Ni, Xiao-Rui Yu, Ji Chen, Bing-Dong Sui
date: 2025/01/06
journal: Theranostics
title: Adipose-derived mesenchymal stem cells combined with platelet-rich plasma are superior options for the treatment of osteoarthritis
authors: He Weijie, Zhao Jie, Liu Jiafei, Wang Fangxing, Xu Zhenyu
date: 2025/01/02
journal: Journal of Orthopaedic Surgery and Research
title: Distinct biological characteristics of mesenchymal stem cells separated from different components of human placenta
authors: Xiangxiong Deng, Su Zhang, Quan Qing, Pengfei Wang, Haiyang Ma, Qinghua Ma, Weixiang Zhao, Hanjing Tang, Min Lu
date: 2024/06/13
journal: Biochemistry and Biophysics Reports
title: BACH2-mediated CD28 and CD40LG axes contribute to pathogenesis and progression of T-cell lymphoblastic leukemia
authors: Feng Min, Zhang Bailing, Li Guilan, Yang Yan, Liu Jiangyuan, Zhang Ziting, Zhou Bing, Zhang Han
date: 2024/01/17
journal: Cell Death & Disease
title: CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
authors: Wei Ye, Xu Tingting, Li Chong, Zhou Xin, Qian Wei, Shen Chunying, Wang Qifeng, Xing Xing, Ou Xiaomin, He Xiayun, Yin Hongmei, Hu Chaosu, Wang Yu, Ji Qinghai, Su Fengtao, Lu Xueguan
date: 2023
journal: Cancer Immunology Research
title: Hsa_circ_0073453 modulates IL-8 secretion by GC-MSCs to promote gastric cancer progression by sponging miR-146a-5p
authors: Chen Wu, Xiaoli Cao, Juan Xu, Lin Wang, Jiaying Huang, Jing Wen, Xiang Wang, Xiao Sang, Wei Zhu, Yongliang Yao, Chenglin Zhou, Feng Huang, Mei Wang
date: 2023
journal: INTERNATIONAL IMMUNOPHARMACOLOGY
title: Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease
authors: Haodong Ding, Yuwei Li, Maoxin Fang, Jiaojiao Chen, Lipin Liu, Zhigang Lu, Jia Hou, Min Luo
date: 2023
journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
title: Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells
authors: Dongxin Wang, Qungang Zhou, Xiang Qiu, Xiaomei Liu, Chun Zhang
date: 2022
journal: BIOMEDICINE & PHARMACOTHERAPY
title: A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities
authors: Lv, Liangyin, Wang, Hui, Shi, Wenqiang, Wang, Yang, Zhu, Wen, Liu, Zexin, Chen, Xiaoqu, Zheng, Chen, Kong, Wencheng, Li, Wei, Zhu, Jianwei, Lu, Huili
date: 2022
journal: APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
title: Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis
authors: Lin, Hexin, Xia, Lu, Lian, Jiabian, Chen, Yinan, Zhang, Yiyi, Zhuang, Zhicheng, Cai, HuaJun, You, Jun, Guan, Guoxian
date: 2021
journal: Journal of Translational Medicine
title: A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
authors: Wu Yang, Chen Dan, Lu Ya, Dong Shu-Chen, Ma Rong, Tang Wei-yan, Wu Jian-qiu, Feng Ji-Feng, Wu Jian-Zhong
date: 2021
journal: CANCER GENE THERAPY
title: Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer:
authors: Feng Yu, Xiaoyan Wang, Hui Shi, Maorong Jiang, Jun Xu, Min Sun, Qinggang Xu, Frank Peprah Addai, Haifeng Shi, Jie Gu, Yang Zhou, Liqiong Liu
date: 2020
journal: Tumori Journal
title: Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma
authors: Xin Tang, Fujun Liu, Zhiyong Liu, Yi Cao, Zongliang Zhang, Yuelong Wang, Jianhan Huang, Shuangming Fan, Shasha Zhao, Yaxin Chen, Gaowei Li, Shan Wang, Meijun Zheng, Yating Hu, Hongjian Li, Caiying Jiang, Meijia Yang, Hui Yang, JianGuo Xu, Gang Guo, Aiping Tong, Liangxue Zhou
date: 2020
journal: Clinical & Translational Immunology
MDSD
Reviews
Write Your Own Review
Related Products
Check items to add to the cart or
